

Resource Summary Report

Generated by [RRID](#) on Aug 9, 2026

CD326 (EpCAM)-FITC, human

RRID:AB_244192

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-080-301, RRID:AB_244192

Antibody Information

URL: http://antibodyregistry.org/AB_244192

Proper Citation: Miltenyi Biotec Cat# 130-080-301, RRID:AB_244192

Target Antigen: CD326 (EpCAM)

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 2021; Target Distribution cancer stem cells, epithelial cells, lung, ES and iPS cells; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-263. (RRID:AB_2726064).

Antibody Name: CD326 (EpCAM)-FITC, human

Description: This monoclonal targets CD326 (EpCAM)

Target Organism: human

Clone ID: HEA-125

Antibody ID: AB_244192

Vendor: Miltenyi Biotec

Catalog Number: 130-080-301

Record Creation Time: 20250820T063315+0000

Record Last Update: 20250821T002447+0000

Ratings and Alerts

No rating or validation information has been found for CD326 (EpCAM)-FITC, human.

Warning: Discontinued: 2021

Discontinued: 2021; Target Distribution cancer stem cells, epithelial cells, lung, ES and iPS cells; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-263. (RRID:AB_2726064).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Gupta T, et al. (2024) Tracking in situ checkpoint inhibitor-bound target T??cells in patients with checkpoint-induced colitis. Cancer cell, 42(5), 797.

Tamai K, et al. (2022) iPSC-derived mesenchymal cells that support alveolar organoid development. Cell reports methods, 2(10), 100314.

Zhang Z, et al. (2020) Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer cell, 38(2), 279.

Apicella M, et al. (2018) Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. Cell metabolism, 28(6), 848.